Cinnulin PF (Cinnamomum burmannii)

Cinnulin PF is a patented, water-soluble extract of Cinnamomum burmannii standardized for Type-A doubly linked procyanidin polymers, which activate insulin receptor signaling by phosphorylating the insulin receptor substrate (IRS-1) and upregulating GLUT4 transporter translocation. This mechanism enhances cellular glucose uptake and improves insulin sensitivity without requiring full insulin secretion.

Origin & History

Cinnulin PF is a water-soluble extract derived from Cinnamomum burmannii (Indonesian cinnamon), standardized for polyphenolic type-A polymers, specifically double-linked procyanidin flavonoids. The extract is produced through a water extraction process that isolates the bioactive fraction containing these procyanidin polymers, representing a concentrated, standardized form of cinnamon designed for metabolic health applications.

Historical & Cultural Context

While the research indicates that cinnamon (Cinnamomum burmanni) has accumulated evidence of beneficial effects in type-2 diabetes which prompted commercialization of supplemental forms, specific details regarding historical traditional medicine use or which traditional medicine systems employed it are not provided in the available sources.

Health Benefits

• Reduces fasting blood glucose by 8.4% in prediabetic individuals over 12 weeks (moderate evidence from human trials)
• Significantly lowers HbA1c and improves β-cell function in Type 2 diabetes patients (strong evidence from 210-person RCT)
• Decreases total and LDL cholesterol at 500mg daily dosing (moderate evidence from controlled trials)
• Improves systolic blood pressure and body composition (preliminary evidence from 12-week study)
• Enhances insulin sensitivity and reduces insulin resistance (moderate evidence from multiple studies)

How It Works

Cinnulin PF's Type-A procyanidin polymers activate insulin receptor tyrosine kinase, promoting phosphorylation of IRS-1 and downstream activation of the PI3K/Akt pathway, which drives GLUT4 vesicle translocation to the cell membrane and increases glucose uptake in skeletal muscle and adipose tissue. The extract also inhibits protein tyrosine phosphatase 1B (PTP1B), an enzyme that normally dephosphorylates and deactivates the insulin receptor, thereby prolonging insulin signaling. Additionally, Cinnulin PF has demonstrated HMG-CoA reductase inhibitory activity, partially explaining its observed reductions in LDL cholesterol at 500 mg daily doses.

Scientific Research

A randomized controlled trial in 210 individuals with Type 2 diabetes showed significant reductions in fasting plasma glucose and HbA1c with 250-500mg daily of cinnamon extract over 4 months. A 12-week study in prediabetic subjects demonstrated an 8.4% decrease in fasting blood glucose with Cinnulin PF supplementation. Multiple systematic reviews and meta-analyses support cinnamon's effects on glycemic control and lipid profiles in Type 2 diabetes patients.

Clinical Summary

A landmark 210-participant randomized controlled trial found that 500 mg of Cinnulin PF daily significantly reduced HbA1c levels and improved β-cell function in Type 2 diabetes patients over 12 weeks, representing strong human trial evidence. A separate human trial in prediabetic individuals documented an 8.4% reduction in fasting blood glucose over the same 12-week period, categorized as moderate evidence given smaller sample sizes. At the 500 mg daily dose, statistically significant reductions in total cholesterol and LDL cholesterol have been observed in multiple trials, though lipid evidence remains secondary to glucose outcomes. Evidence is currently insufficient to recommend Cinnulin PF as a standalone diabetes treatment, and it is best characterized as an adjunctive blood sugar support compound.

Nutritional Profile

Cinnulin PF is a patented water-soluble extract of Cinnamomum burmannii bark, standardized to contain concentrated Type-A doubly linked procyanidin polymers (polyphenolic polymers), which are the primary bioactive compounds responsible for its insulin-mimetic effects. As an extract rather than whole spice, macronutrient content is negligible per typical 250–500mg serving. Key bioactive compounds include: Type-A procyanidins (oligomeric proanthocyanidins) at standardized concentrations, cinnamaldehyde (present in reduced amounts compared to whole cinnamon due to water-based extraction process that removes fat-soluble volatile oils), and methylhydroxychalcone polymer (MHCP), which activates insulin receptor signaling pathways. The water-based extraction process specifically concentrates the water-soluble polyphenolic fraction while substantially reducing coumarin content to approximately 0.0004% or less per serving (versus up to 1% in whole Cassia cinnamon), making it significantly safer for chronic use than whole cinnamon powder. Trace minerals from the bark matrix may include manganese (~0.1–0.2mg per 500mg dose) and calcium. Bioavailability is enhanced relative to whole cinnamon because the extraction process removes insoluble fiber and lipid components that may impede polyphenol absorption; the Type-A procyanidins are partially absorbed in the small intestine with additional colonic fermentation yielding phenolic metabolites. No significant vitamin or dietary fiber content is present at standard supplemental doses.

Preparation & Dosage

Clinically studied dosage: 250-500mg daily of Cinnulin PF standardized for polyphenolic type-A polymers. In cell culture studies, 20 µg/mL was identified as the optimal non-toxic concentration. Treatment durations in clinical trials ranged from 12 weeks to 4 months. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Chromium picolinate, Alpha-lipoic acid, Berberine, Bitter melon extract, Gymnema sylvestre

Safety & Interactions

Cinnulin PF is generally well tolerated at doses of 250–500 mg daily, with no serious adverse events reported in clinical trials up to 12 weeks; the water-soluble extraction process removes fat-soluble coumarin, substantially reducing the liver toxicity risk associated with whole cinnamon powder. Individuals taking insulin, metformin, sulfonylureas, or other hypoglycemic agents should use Cinnulin PF cautiously, as additive blood-glucose-lowering effects may increase hypoglycemia risk and require medication adjustment under physician supervision. Pregnant and breastfeeding women should avoid Cinnulin PF due to insufficient safety data in these populations, and individuals with known hypersensitivity to Cinnamomum species should not use the extract. Those on anticoagulant therapies such as warfarin should consult a physician, as cinnamon-derived compounds may have mild antiplatelet properties that could potentiate bleeding risk.